UB Paderborn / Katalog / Suche / in CDI

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.476-487

2012

Link zum Volltext

Verfügbarkeit prüfen

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Cancer discovery, 2018-02, Vol.8 (2), p.216-233

2018

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Molecular cancer therapeutics, 2016-05, Vol.15 (5), p.783-793

2016

Link zum Volltext

Verfügbarkeit prüfen

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

Science translational medicine, 2017-04, Vol.9 (387)

2017

Link zum Volltext

Verfügbarkeit prüfen

CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury

American journal of physiology. Renal physiology, 2014-02, Vol.306 (4), p.F379-F388

2014

Link zum Volltext

Verfügbarkeit prüfen

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.635-646

2020

Link zum Volltext

Verfügbarkeit prüfen

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Oncotarget, 2017-06, Vol.8 (26), p.42343-42358

2017

Link zum Volltext

Verfügbarkeit prüfen

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis

Genes & development, 2003-07, Vol.17 (13), p.1581-1591

2003

Link zum Volltext

Verfügbarkeit prüfen

PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2

Nature cell biology, 2002-11, Vol.4 (11), p.865-870

2002

Link zum Volltext

Verfügbarkeit prüfen

Regulation of survivin by ErbB2 signaling : Therapeutic implications for ErbB2-overexpressing breast cancers

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1640-1647

2006

Link zum Volltext

Verfügbarkeit prüfen

Identification of Liver Receptor Homolog-1 as a Novel Regulator of Apolipoprotein AI Gene Transcription

Molecular endocrinology (Baltimore, Md.), 2004-10, Vol.18 (10), p.2378-2387

2004

Link zum Volltext

Verfügbarkeit prüfen

Antisense and Antigene Properties of Peptide Nucleic Acids

Science (American Association for the Advancement of Science), 1992-11, Vol.258 (5087), p.1481-1485

1992

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4414-4414

2019

Link zum Volltext

Verfügbarkeit prüfen

Human tumor suppressor ARF impedes S-phase progression independent of p53

Cancer research (Chicago, Ill.), 2002-02, Vol.62 (4), p.1171-1177

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4426-4426

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of PPARγ overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays

American journal of physiology: endocrinology and metabolism, 2004-09, Vol.287 (3), p.E390-E404

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1522-1522

2018

Link zum Volltext

Verfügbarkeit prüfen

Strand-Invasion of Duplex DNA by Peptide Nucleic Acid Oligomers

Proceedings of the National Academy of Sciences - PNAS, 1993-11, Vol.90 (22), p.10648-10652

1993

Link zum Volltext

Verfügbarkeit prüfen

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

Cancer discovery, 2024-03, Vol.14 (3), p.446

2024

Link zum Volltext

Verfügbarkeit prüfen

Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter

Molecular and Cellular Biology, 1995-05, Vol.15 (5), p.2782-2790

1995

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2824-2824

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1 -amplified cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5994-5994

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1784-1784

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5641-5641

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1322: Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1322-1322

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis

PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2

Regulation of survivin by ErbB2 signaling : Therapeutic implications for ErbB2-overexpressing breast cancers

Identification of Liver Receptor Homolog-1 as a Novel Regulator of Apolipoprotein AI Gene Transcription

Antisense and Antigene Properties of Peptide Nucleic Acids

Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors

Human tumor suppressor ARF impedes S-phase progression independent of p53

Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status

Impact of PPARγ overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays

Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer

Strand-Invasion of Duplex DNA by Peptide Nucleic Acid Oligomers

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter

Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1 -amplified cancers

Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies

Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer

Abstract 1322: Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer

Suchergebnisse filtern